• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

    70.66 +0.76 (+1.09%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about PTC Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
    Via Chartmill
    PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
    Via Chartmill
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
    PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors. 
    Via Chartmill
    Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? ↗
    Via The Motley Fool
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
    PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout. 
    Via Chartmill
    News headline image
    PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
    PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations. 
    Via Chartmill
    News headline image
    Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
    One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
    PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
    Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
    December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
    Via MarketMinute
    News headline image
    Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
    A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
    Via The Motley Fool
    News headline image
    A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗
    Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
    PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities. 
    Via Chartmill
    News headline image
    This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
    A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
    A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
    Via The Motley Fool
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
    PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity. 
    Via Chartmill
    News headline image
    Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
    Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage... 
    Via MarketMinute
    Topics Death
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗
    PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock. 
    Via Chartmill
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
    PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities. 
    Via Chartmill
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗
    PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment. 
    Via Chartmill
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗
    PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile. 
    Via Chartmill
    News headline image
    PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗
    PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech. 
    Via Chartmill
    News headline image
    PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
    BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
    Via Benzinga
    News headline image
    Here's Why Shares in PTC Therapeutics Soared This Week ↗
    An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.